GW Phase III neuropathic pain data

GW Pharmaceuticals (LSE:GWP) said that in a Phase III trial in 125 patients with neuropathic pain, its Sativex sublingual cannabis extract spray improved numerical rating scales of pain compared to placebo spray, the primary endpoint (p<0.01). In the double-blind trial, Sativex also significantly improved allodynia, pain disability index, quality of sleep and patients' global impression of change score (p<0.05, p<0.01, p<0.01 and p<0.01, respectively). Allodynia is the occurrence of pain in response to a normally non-painful stimulus. All patients in the trial remained on existing medications, including opiates, anti-epileptics and antidepressants. ...